H

Halozyme Therapeutics
D

HALO

49.010
USD
3.29
(7.20%)
مغلق
حجم التداول
132,490
الربح لكل سهم
3
العائد الربحي
-
P/E
16
حجم السوق
6,235,395,270
أصول ذات صلة
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.29 USD
    O
    ONCS
    -0.01000
    (-0.44%)
    2.16000 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    X
    XENE
    -1.920
    (-4.60%)
    39.850 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Halozyme Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.